🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07323004
Starting soon Not applicable

Motor Development Assessment and Support for Children With Neurodevelopmental Disorders

NCT07323004 · tracked via the Priya Life Science China tracker
Sponsor
Aiyoudong Children and Youth Sports Health Research Institute
Phase
Not applicable
Started
2026-01-30
Last updated
2026-01-07

Condition(s) studied

Neurodevelopmental Disorders

Investigational drug(s) / intervention(s)

Characteristic Exercise InterventionTraditional Rehabilitation

Characteristic Exercise Intervention: This intervention combines traditional rehabilitation techniques (e.g., occupational therapy and physical therapy focusing on fine and gross motor skills) with a structured, age-appropriate characteristic exercise program. The program includes dynamic balance training, sensory-motor integration activities, rhythmic movement games, and core stability exercises. * Frequency: 3 sessions per week * Duration: 45 minutes per session * Total Intervention Period: 12 weeks * Distinguishing Feature: The inclusion of customized play-based movement training and sensory-motor games designed specifically to support neurodevelopmental improvement in young children with motor delays.

Traditional Rehabilitation: Participants will receive conventional rehabilitation therapy, including basic motor skill exercises, postural control training, and therapist-led occupational therapy sessions aimed at improving daily motor function. * Frequency: 3 sessions per week * Duration: 45 minutes per session * Total Intervention Period: 12 weeks * Distinguishing Feature: This group receives only traditional rehabilitation techniques without any additional structured or characteristic physical activity component.

Study summary

On the one hand, it helps to understand the motor development of preschool children, so as to provide early intervention means for the prevention of motor retardation and promote the healthy development of preschool children, and on the other hand, different motor intervention strategies are formulated according to the developmental characteristics of children with different core symptoms. It is of great academic value to verify the effectiveness of the program through empirical research on exercise intervention and promote the improvement of motor and cognitive development of children with neurodevelopmental disorders.

Eligibility

Sex
ALL
Min age
4 Years
Max age
12 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Children aged 4 to 12 years * Born at full term (gestational age ≥ 37 weeks and \< 42 weeks) * Provided informed consent signed by their legal guardian * For the ADHD group: * Diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) by a qualified physician (e.g., child psychiatrist or psychologist) according to DSM-5 diagnostic criteria * For the typical development (control) group: * No symptoms related to ADHD (e.g., inattention, hyperactivity, impulsivity) * Normal scores on parent- and teacher-rated behavioral questionnaires (e.g., CBCL, SDQ) * No history of neurological or psychiatric disorders Exclusion Criteria: * Diagnosis of other neurodevelopmental disorders, such as: * Autism Spectrum Disorder (ASD) * Learning disabilities * Epilepsy, cerebral palsy, or other neurological conditions * Developmental quotient (DQ) \< 85, as measured by standardized tools (e.g., Gesell scale) * Significant visual or hearing impairments, or congenital malformations * History of high-risk birth events, including but not limited to: * Severe birth asphyxia * Intrauterine infections * Presence of genetic or metabolic disorders, or severe dysfunction of vital organs * For the ADHD group: comorbid psychiatric conditions (e.g., schizophrenia, severe mood disorders)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
China Institute of Sport Science Beijing China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07323004 on ClinicalTrials.gov ↗ ← All trials in China